Plerixafor, as a CXCR4 targeted treatment for lung cancer, is well supported by preclinical or early clinical evidence as a potential therapeutics for lung cancer in combination with chemotherapy, radiotherapy, and immunotherapy. Here, CXCR4 is linked to lung carcinoma.